US 6,309,892 B1 · Antibodies to components of dense microspheres and methods of using the same

Abstract

DMS present in the brain of individuals susceptible to cerebral amyloidosis disintegrate into DMS components to form cerebral amyloid plaques and other DMS components that are removed from the brain via circulating bodily fluids. Detecting the presence of these removed DMS components and/or antibodies thereto in circulating bodily fluids provides a diagnostic mechanism to determine the onset of cerebral amyloid plaque formation. Detecting the presence of these removed DMS components and/or antibodies thereto in circulating bodily fluids also provides a diagnostic mechanism to determine the efficacy of treatment regimes for preventing cerebral amyloid plaque formation. Antibodies also can be raised against isolated DMS components and subsequently utilized in a diagnostic method capable of detecting the onset of cerebral amyloid plaque formation.

Claims7

Dependent claims

A method of detecting the quantity of antibodies to DMS components present in a biological sample, comprising:

(a) contacting a biological sample with at least one component of dense microspheres (DMS) having a molecular weight selected from the group consisting of 8, 10, 12, 16, 19, 21, 25, 28, 30, 31, 33, 40, 45, 48, 52, 60, 66, 70, 80, 100, 110, and 120 kilodaltons;
and
(b) determining the immunoreactivity of said component with said biological sample,
wherein the quantity of antibodies to DMS components in the biological sample corresponds to the immunoreactivity of the DMS component with the biological sample.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

08/660,886Filed 10 Jun 1996 · division

Priority

27 Aug 1986

Granted

30 Oct 2001

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

A61K 31/35
Having oxygen as the only ring hetero atom, e.g. fungichromin: having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…
A61K 31/42
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: oxazoles
A61K 31/505
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrimidines; Hydrogenated…

Family

Application06/901,007Parent of this continuation-in-part · filed 27 Aug 1986

Application07/021,242Parent of this continuation · filed 3 Mar 1987

Application07/315,796Parent of this continuation-in-part · filed 27 Feb 1989

Application07/493,276Parent of this continuation · filed 14 Jun 1990

Application08/077,641Parent of this continuation-in-part · filed 17 Jun 1993

Application08/168,250Parent of this division · filed 17 Dec 1993

US 5,525,339 AParent of this division

Application08/168,250Parent of this continuation-in-part

Application08/077,641Parent of this continuation

US 5,231,170 AParent of this continuation

Application07/493,276Parent of this continuation-in-part

US 4,919,915 AParent of this continuation-in-part

Application07/315,796Parent of this continuation

US 4,816,416 AParent of this continuation

Application07/021,242Parent of this continuation-in-part

US 6,309,892 B1This patent

From the US filing history. Foreign family members aren’t listed.

Antibodies to components of dense microspheres and methods of using the same

Life of this patent

Antibodies to components of dense microspheres and methods of using the same

Life of this patent

Abstract

Claims7